eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
Gene-based agents for the treatment of congenital eye diseases
Pharmacologists at LMU have developed gene-based agents for the treatment of congenital eye diseases. The first of these is now undergoing a phase-I clinical trial in color-blind patients at the University Medical Center in Tübingen. Is this approach translatable in principle to other visual disorders? Michalakis: About 200 genes have been identified which, when mutated,…
Biodegradable nanoparticles slip through mucus
Researchers at Johns Hopkins University (JHU) have created biodegradable, ultra tiny, nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The interdisciplinary team of researchers, led by Justin Hanes of the JHU Center for Nanomedicine, developed the nanoparticles so that they not only penetrate…
Regular Eye Exams Can Detect Diabetes
“People with diabetes are 10 to 20 times more likely to go blind than someone without the condition, due to diabetic retinopathy. However, if this condition is detected early through an eye examination and treated, blindness can be prevented in 90% of cases” http://www.irishhealth.com/article.html?id=20014
FDA approves first retinal implant for rare eye disease
The U.S. Food and Drug Administration has approved the first artificial retina, an implanted device that replicates some of the function of the retina, helping to restore vision to people blinded with a rare genetic disorder. The device is intended to replace the function of light-sensing cells in the retina destroyed by retinitis pigmentosa, an…
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for…
Intraocular therapy prevents or reverses diabetic retinopathy in mice
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on…
